Journal of Traditional Chinese Medicine >
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 expression and its relationship with T cell activation in human immunodeficiency virus/acquired immune deficiency syndrome patients with lung-spleen Qi deficiency syndrome pattern
Received date: 2021-04-26
Accepted date: 2021-07-08
Online published: 2022-04-08
Supported by
National Natural Science Foundation of China (Construction of HIV Pseudovirus Infected Cell Model and Application of Yiaikang in the Study of T Cell Immune Response)(82004207);National Special Science and Technology Program on Major Infectious Diseases (Study on the Scheme of TCM to Reduce the Incidence of Adverse Reactions to AIDS Antiviral Therapy)(2017ZX10205502002);Study on the Scheme of TCM to Reduce the Incidence of AIDS Opportunistic Infection(2017ZX10205502003);Science and Technology Tackling Plan of Henan Province (Exploring the Activation Mechanism of Yiaikang on CD8+ T Lymphocytes in HIV/AIDS Patients based on STING/SAMHD1 Pathway)(202102310178);Regulation of HIV/AIDS Treg Cell-Derived Exosomeso on Activation of CD4+ T Cells and the Intervention of Yiaikang(212102311126);Subject Construction Project of Henan Characteristic Backbone Subject of TCM of Henan University of TCM (Deep Sequencing/Molecular Docking/Gene Editing Network System to Analyze The Mechanism of TCM Regulating the Immune Function of HIV Patients)(STG-ZYXKY-2020029);Henan Province TCM Research Project (Explore the Mechanism of Yiaikang in the Treatment of AIDS Immunity Based on HIV gag-CTL Response)(2018JDZX106);Henan Province TCM Research Project (Explore the Mechanism of Yiaikang in the Treatment of AIDS Immunity Based on HIV gag-CTL Response)(2019AZB003);Henan Province TCM Research Project (Study on TCM Treatment of Aged AIDS)(20-21ZYZD03);Key Scientific Research Projects of Colleges and Universities in Henan Province (to Explore the Regulation Mechanism of Yiaikang on AIDS Lung Qi Deficiency Syndrome from TGF-β /Smad/ID)(20A360010)
OBJECTIVE: To investigate the relationship between antiviral restriction factor Sterile Alpha Motif and Histidine-Aspartic acid domain-containing protein 1 (SAMHD1) expression and T cell activation, furthermore, identifying objective indexes of lung-spleen Qi deficiency symptom pattern.
METHODS: We assessed the profile of T lymphocyte subsets, characteristics of SAMHD1 and human leukocyte antigen DR (HLA-DR) expression in lung-spleen Qi deficiency patients. At the same time, people living with human immunodeficiency virus / acquired immune deficiency syndrome (HIV/AIDS) (PLWHA) without obvious clinical symptoms and healthy donors in this area were used as controls.
RESULTS: Immunohematologic indexes lower CD4 count, lower CD4/CD8 ratio and higher SAMHD1 level were found in lung-spleen Qi deficiency patients. Furthermore, we demonstrated a positive relationship between SAMHD1 and HLA-DR level as well as with interferon factor in lung-spleen Qi deficiency syndrome and patients without obvious clinical signs and symptoms groups.
CONCLUSIONS: These data indicated the positive relationship between SAMHD1 and T cell activation which further elucidated the role of SAMHD1 in cellular immune response. Furthermore, combination of T lymphocyte subsets counts and SAMHD1 level may be used as clinical and biological reference basis for the differentiation and diagnosis of HIV / AIDS traditional Chinese medicine syndromes.
Zhen LIU , Qingyan ZHANG , Bowen DENG , Feng SANG , Danni WANG , Ning KANG , Jie LI , Min ZHANG , Shoupei LIANG , Chenchen DUAN , Zhibin LIU , Qianlei XU , Qiang LI . Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 expression and its relationship with T cell activation in human immunodeficiency virus/acquired immune deficiency syndrome patients with lung-spleen Qi deficiency syndrome pattern[J]. Journal of Traditional Chinese Medicine, 2022 , 42(3) : 451 -457 . DOI: 10.19852/j.cnki.jtcm.20220408.004
| 1 | Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30:305-8. |
| 2 | Koofhethile CK, Ndhlovu ZM, Thobakgale-Tshabalala C, et al. CD8+ T cell breadth and ex vivo virus inhibition capacity distinguish between viremic controllers with and without protective HLA class I allele. J Virol 2016; 90:6818-31. |
| 3 | Han C, Kawana-Tachikawa A, Shimizu A, et al. Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology 2014; 11:38. |
| 4 | Smith KN, Mailliard RB, Piazza PA, et al. Effective cytotoxic T lymphocyte targeting of persistent HIV-1 during antiretroviral therapy requires priming of naive CD8+ T cells. mBio 2016; 7:e00473-16. |
| 5 | Zhang M, Robinson T O, Duverger A, et al. Regulatory CD4 T cells inhibit HIV-1 expression of other CD4 T cell subsets via interactions with cell surface regulatory proteins. Virology 2018; 516:21-9. |
| 6 | Li N, Zhang W, Cao X. Identification of human homologue of mouse IFN-gamma induced protein from human dendritic cells. Immunol Lett 2000; 74:221-4. |
| 7 | Goldstone DC, Ennis-Adeniran V, Hedden JJ, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011; 480:379-82. |
| 8 | White T E, Brandariz-Nunez, Valle-Casuso J C, et al. Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology 2013; 436:81-90. |
| 9 | Enrique M G, Jose B M, Zhengyu O, et al. Potent cell-intrinsic immune responses in dendritic cells facilitate HIV-1-specific T cell immunity in HIV-1 elite controllers. PloS Pathog 2015; 11:e1004930. |
| 10 | Coquel F, Neumayer C, Lin Y L, et al. SAMHD1 and the innate immune response to cytosolic DNA during DNA replication. Curr Opin Immunol 2019; 56:24-30. |
| 11 | Antonucci JM, Kim SH, St Gelais C, et al. SAMHD1 impairs HIV-1 gene expression and negatively modulates reactivation of viral latency in CD4+ T cells. J Virol 2018; 92:e00292-18. |
| 12 | Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol 2016; 46:292-307. |
| 13 | Liu ZB, Yang JP, Xu LR. Effectiveness and safety of Traditional Chinese Medicine in treating acquired immune deficiency syndrome: 2004-2014. Infect Dis Poverty 2015; 4:59. |
| 14 | Xu QL, Ma YQ, Xu XQ, et al. Practices and thoughts of clinical research in the prevention and treatment of AIDS with TCM. Zhong Hua Zhong Yi Yao Za Zhi 2018; 33:5285-9. |
| 15 | Liu ZB, Yang JP. Health related quality of life: is it another comprehensive evaluation indicator of Chinese medicine on acquired immune deficiency syndrome treatment? J Tradit Chin Med 2015; 35:600-5. |
| 16 | Jin Y, Wang X, Li Z, et al. Survival of AIDS patients treated with Traditional Chinese Medicine in rural central China: a retrospective cohort study, 2004-2012. Evid Based Complement Alternat Med 2015; 2015:282819. |
| 17 | Zou W, Wang J, Liu Y. Effect of Traditional Chinese Medicine for treating human immunodeficiency virus infections and acquired immune deficiency syndrome: boosting immune and alleviating symptoms. Chin J Integr Med 2016; 22:3-8. |
| 18 | Xian QF, Lan Y, Zou W, et al. Discussion on Chinese medicine treatment of AIDS from immune reconstruction. Zhong Hua Zhong Yi Yao Za Zhi 2020; 35:1882-4. |
| 19 | Zhao Y, He L, Xie Q, et al. A novel classification method for syndrome differentiation of patients with AIDS. Evid Based Complement Alternat Med 2015; 2015:936290. |
| 20 | Xie SP, Chen JS, Liu AH, et al. Logistic analysis on quantitive diagnosis of deficient syndromes of HIV/AIDS. Zhong Hua Zhong Yi Yao Za Zhi 2010; 25:1663-5. |
| 21 | Wang J, Liu Y, He LY, et al. Distribution and development rules of Chinese medicine syndromes in 2237 cases of HIV/AIDS. Zhong Yi Za Zhi 2012; 53:948-51. |
| 22 | Shen YZ. Interpretation of guidelines for diagnosis and treatment of AIDS in China (2018). Chuan Ran Bing Xin Xi Za Zhi 2019; 32:16-20. |
| 23 | Xu QL, Wu XW, Xie SP, et al. Study on standardization research of AIDS Traditional Chinese Medicine syndromes. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2012; 18:323-5. |
| 24 | Vigón L, Rodríguez-Mora S, Luna A, et al. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochem Pharmacol 2020; 182:114203. |
| 25 | Saraiva DP, Jacinto A, Borralho P, et al. HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy. Front Immunol 2018; 9:2605. |
| 26 | Liu S, Chen Y, Xie S, et al. Gene expression profiles of HIV/AIDS patients with Qi-Yin deficiency and dampness-heat retention. J Altern Complement Med 2016; 22:865-79. |
| 27 | Wen L, Liu YF, Jiang C, et al. Comparative proteomic profiling and biomarker identification of Traditional Chinese Medicine-based HIV/AIDS syndromes. Sci Rep 2018; 8:4187. |
| 28 | Ren ZX, Xie SP, Wang Z, et al. Research on relationship between amount of CD4 + T or CD8 + T lymphocyte subsets and CD4 + T amount in HIV/AIDS patients with Qi deficiency of spleen and lung. Zhong Hua Zhong Yi Yao Za Zhi 2014; 29:1064-6. |
| 29 | Eva RM, Alba R, Eduardo P, et al. Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. J Antimicrob Chemother 2014; 69:3057-60. |
| 30 | Xie J, Qiu Z, Han Y, et al. The correlation between HLA-DR or CD38 expression in CD8(+) T cells and CD4(+) T cells count in treatment-naive HIV/AIDS patients. Zhong Hua Nei Ke Za Zhi 2016, 55:36-9. |
| 31 | Cai Y, Abdel-Mohsen M, Tomescu C, et al. BCL6 inhibitor-mediated downregulation of phosphorylated SAMHD1 and T cell activation are associated with decreased HIV infection and reactivation. J Virol 2019; 93:e01073-18. |
| 32 | Li J, Gao C, Huang S, et al. SAMHD1 expression is associated with low immune activation but not correlated with HIV-1 DNA levels in CD4+ T cells of patients with HIV-1. Mol Med Rep 2020; 22:879-85. |
| 33 | Yang S, Zhan Y, Zhou Y, et al. Interferon regulatory factor 3 is a key regulation factor for inducing the expression of SAMHD1 in antiviral innate immunity. Sci Rep 2016; 6:29665. |
| 34 | Riess M, Fuchs NV, Idica A, et al. Interferons induce expression of SAMHD1 in monocytes through down-regulation of miR-181a and miR-30a. J Biol Chem 2017; 292:264-77. |
/
| 〈 |
|
〉 |